Benzinga | Sep 30, 2021 09:24AM EDT

Conformis Posts Clinical Study Data For Its Knee Implants

* Conformis Inc (NASDAQ:CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant.

* Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.

* 89% of the patients reported being either satisfied or highly satisfied.

* The researchers reviewed patient records and conducted patient report outcome surveys of 540 knees in 433 patients who underwent personalized total knee arthroplasty.

* Related Link: Investors React To Conformis' Annual Sales Guidance Update.

* Price Action: CFMS stock is up 1.55% at $1.31 during the premarket session on the last check Thursday.